



(51) International Patent Classification:

A61K 31/353 (2006.01) A61P 17/16 (2006.01)
A61K 31/355 (2006.01) A61P 21/00 (2006.01)
A61P 9/12 (2006.01) A61P 29/00 (2006.01)
A61P 17/14 (2006.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/AU2013/001310

(22) International Filing Date:

13 November 2013 (13.11.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

AU 2012904937 13 November 2012 (13.11.2012) AU
AU 2012905406 11 December 2012 (11.12.2012) AU

(71) Applicant: **GORDAGEN PHARMACEUTICALS PTY LTD** [AU/AU]; ACN: 161 094382, 90 Queensbridge Street, Southbank, Victoria 3006 (AU).

(72) Inventor: **TONG, Glenn**; 9/8 Wallen Road, Hawthorn, Victoria 3122 (AU).

(74) Agent: **LANCASTER LEGAL PTY LTD**; 14/200 Canterbury Road, Bayswater, Victoria 3153 (AU).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: TRANSMUCOSAL DELIVERY OF TOCOTRIENOL

Figure 8



(57) Abstract: The present invention relates to pharmaceutical compositions formulated for transmucosal delivery, and in particular sublingual delivery, comprising at least one tocotrienol or derivative thereof together with one or more pharmaceutically acceptable excipients. The present further relates to the use of said compositions for treating or preventing post exercise muscle soreness, delayed onset muscle soreness, cardiac fibrosis, hypertension, inflammation, stroke, cancer, elevated cholesterol and/or triglycerides, baldness, hypertrophy, conditions resulting from radiation exposure, stabilizing and/or controlling blood glucose levels, and improving exercise endurance and capacity.